Regeneron Pharmaceuticals
REGN
671 hedge funds and large institutions have $27.4B invested in Regeneron Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 111 funds opening new positions, 226 increasing their positions, 222 reducing their positions, and 81 closing their positions.
37% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 81
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
4% more funds holding
Funds holding: 644 → 671 (+27)
2% more repeat investments, than reductions
Existing positions increased: 226 | Existing positions reduced: 222
0.49% less ownership
Funds ownership: 69.44% → 68.96% (-0.49%)
8% less capital invested
Capital invested by funds: $29.8B → $27.4B (-$2.4B)
24% less call options, than puts
Call options by funds: $755M | Put options by funds: $994M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$236M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$121M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$85.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.7M |
| 5 |
D.E. Shaw & Co
New York
|
+$57.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$391M |
| 2 |
Janus Henderson Group
London,
|
-$222M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$77.2M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$67.8M |
| 5 |
O
OrbiMed
New York
|
-$63.1M |
REGN Hedge Fund Activity: Q4 2018 in Review
671 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2018, worth a combined $27.4B — down 8% from $29.8B a quarter earlier.
Buyers outnumbered sellers: 111 funds opened new REGN positions and 81 closed out — a net gain of 30 holders — while 226 added to existing stakes and 222 trimmed.
The largest buyer was Capital World Investors, adding an estimated $236M. The largest seller was Wellington Management Group, cutting an estimated $391M.
- 671 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2018, up from 644 in Q3 2018.
- Funds reported $27.4B of Regeneron Pharmaceuticals stock for Q4 2018, down 8% quarter-over-quarter.
- 111 funds opened new Regeneron Pharmaceuticals positions in Q4 2018 and 81 closed out, a net change of +30 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2018 was Capital World Investors, an estimated $236M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2018 was Wellington Management Group, an estimated $391M sold.
Based on aggregated 13F filings for Q4 2018.